When screening for the best penny stock to buy now, profitability, liquidity and risk tolerance all come in to play which is why NeoStem Inc. (AMEX NPS) makes for an interesting investment. A penny stock like this provides exposure to the world of cutting edge stem cell therapeutics and allure of developing markets- at the same time, it has the transparency of a US based company, and the stability of solid revenues.
NeoStem, Inc. is an international biopharmaceutical company with adult stem cell operations in the U.S., a network of adult stem cell therapeutic providers in China as well as a 51% ownership interest in a profitable Chinese generic pharmaceutical manufacturing company. By far the most transformative event has been the company’s recent acquisition of a Chinese pharmaceuticals manufacturer. This has not only provided the company with its first source of any significant revenue but also a springboard for launching new therapies.
Based in New York, New York, NeoStem’s stock is traded under the symbol NBS on the American Stock exchange (AMEX) and has 611 listed full time employees.
Website: http:// http://www.neostem.com /
Company Snapshot:
| Trading Symbol: | AMEX: NBS |
| Last Price: | $0.65 |
| Avg Vol (3 month): | 337,721 |
| Avg Vol (10 day): | 401,314 |
| Market Cap: | 69.77M |
| EBITDA (ttm)6: | -20.01M |
| Total Cash (mrq): | $11.71M |
| Shares Outstanding: | 107.32 million shares |
| Float: | 69.63 million shares |
| Shares Held by Insiders: | 5% |
| Institutions Holding Shares: | 48 |
| Top Institutional Holder: | 1,272,395 shares Perceptive Advisors LLC (as of 9/30/2011) |
| Top Mutual Fund Holder: | 697,970 shares iShares Russell 2000 Index Fund (as of 10/31/2011) |
| Contact Information: | 420 Lexington Avenue Suite 450 New York, NY 10170 |
| Investor/Analyst inquiries: | Robin Smith, CEO 212.584.4174 rsmith@neostem.com |
| Next Earnings Date: | March 26, 2012 |
| Profitability Margin (ttm) | -46.60% |
| Operating Margin(ttm): | -39.68% |
| Return On Assets(ttm): | -12.86% |
| Return On Equity(ttm): | -35.95% |
| Qtrly Revenue Growth (yoy): | 7.80% |
| Operating Cash Flow(ttm): | $-22.82M |
| Levered Free Cash Flow(ttm): | $-13.13M |
NBS closing price January 19, 2012 was $0.6501, up 0.07, on volume of 924,196.
NBS is trading 16.91% above its 50 day moving average and -8.07% below its 200 day moving average.
NBS is -69.04% below its 52-week high of $2.10 and 51.19% above its 52-week low of $0.43.
NBS‘s PE ratio is N/A and its market cap is $69.77M.
NBS was upgraded by analysts at WBB Securities from a “speculative buy” rating to a “buy” rating. They now have a $2.00 price target on the stock, up previously from $1.85.
NBS was one of the stocks featured in our Good Stocks To Buy Now: January 20, 2012 post ealier today
About AimHighProfits.com
AimHighProfits.com strives to provide you with the hottest stock alerts in the market in Real-Time. We focus on stocks that trade for $5 per share or less, some as little as a few pennies with upside potential. Our goal is committed to producing and publishing the highest-quality insight and analysis of small-cap stocks, emerging technology stocks, hot penny stocks and helping investors make informed decisions and to inform you of the best stocks in the market before they move. Our focus is primarily on OTC stocks in the stock market today which have traditionally been ignored by Wall Street.
We have particular expertise with internet stocks, gold stocks, renewable energy stocks, biotech stocks, oil stocks and green energy stocks. There are many hot penny stock opportunities present in the OTC market every day and we seek to exploit these hot stock gains for our members before the average daytrader is made aware of them.
Aim High Profits Disclaimer
This is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances.
AimHighProfits.com is a wholly-owned subsidiary of Kelevra Media Innovation.
While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
For a complete explanation, please visit our disclaimer page.
ShareJAN
